Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C39H49ClN4O2 |
| Molecular Weight | 641.285 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=C(CC2=NN(C[C@H]3CCCN3CCCCC4=CC=C(OCCCN5CCCCCC5)C=C4)C(=O)C6=C2C=CC=C6)C=C1
InChI
InChIKey=YANGEESWIGIKOP-UUWRZZSWSA-N
InChI=1S/C39H49ClN4O2/c40-33-19-15-32(16-20-33)29-38-36-13-3-4-14-37(36)39(45)44(41-38)30-34-12-9-27-43(34)26-8-5-11-31-17-21-35(22-18-31)46-28-10-25-42-23-6-1-2-7-24-42/h3-4,13-22,34H,1-2,5-12,23-30H2/t34-/m1/s1
GSK-1004723 is a dual histamine H(1) and H(3) receptor antagonist with a long duration of action that has been investigated for the treatment of allergic rhinitis. GSK-1004723 was designed for intranasal administration as a suspension or solution. Clinical trials (phase 1 and 2) showed that GSK-1004723 is well tolerated and demonstrates clinically significant attenuation of symptoms (tested in an environmental allergen challenge chamber). However, attenuation of symptoms was less than seen for treatment with cetirizine (a commonly used over-the-counter antihistamine).
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
955359-72-5
Created by
admin on Sat Dec 16 03:01:36 GMT 2023 , Edited by admin on Sat Dec 16 03:01:36 GMT 2023
|
PRIMARY | |||
|
DB12806
Created by
admin on Sat Dec 16 03:01:36 GMT 2023 , Edited by admin on Sat Dec 16 03:01:36 GMT 2023
|
PRIMARY | |||
|
17747460
Created by
admin on Sat Dec 16 03:01:36 GMT 2023 , Edited by admin on Sat Dec 16 03:01:36 GMT 2023
|
PRIMARY | |||
|
S08212J4ZR
Created by
admin on Sat Dec 16 03:01:36 GMT 2023 , Edited by admin on Sat Dec 16 03:01:36 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
